



In another aspect, there is provided a process for the preparation of a compound as defined herein comprising any of the following steps:

(a) a reaction of a compound of formula (V),




5 with an acid followed by urea formation with amine R^4NH_2 in the presence of a phosgene equivalent;

(b) a reaction of a compound of formula (VII),




10 with an acid followed by urea formation with amine R^4NH_2 in the presence of a phosgene equivalent;

(c) a reaction of a compound of formula (IX),



with $R^7-B(OH)_2$; or

(d) a reaction of a compound of formula (X),



with halide via Suzuki-Miyaura reaction;

wherein R^2 , R^3 , R^4 are as defined herein;

- 5 R^5 and R^6 together with the nitrogen atom they are attached to form a 3-7 membered heterocyclyl; and

R^7 is aryl or heteroaryl.

In another aspect, there is provided a compound or pharmaceutically acceptable salts, enantiomers or diastereomers as defined herein for use as therapeutically active substance.

- 10 In another aspect, there is provided a pharmaceutical composition comprising a compound as defined herein and a therapeutically inert carrier.

In another aspect, there is provided use of a compound as defined herein for the preparation of a medicament for the treatment or prophylaxis of hepatitis B virus infection.

- 15 In another aspect, there is provided a compound or pharmaceutically acceptable salt, enantiomer or diastereomer as defined herein for use in the treatment or prophylaxis of hepatitis B virus infection.

In another aspect, there is provided a compound or pharmaceutically acceptable salt, enantiomer or diastereomer as defined herein, when manufactured according to a process as defined herein.

20 DETAILED DESCRIPTION OF THE INVENTION

DEFINITIONS

(6S)-3-[(2R,3R,4S)-4-hydroxy-2-methyl-5-oxo-3-pyrimidin-2-yloxy-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide;

(6S)-6-methyl-3-(2-oxo-4-pyrimidin-2-yl-pyrrolidin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide;

(6S)-3-(3-hydroxy-2-oxo-4-phenyl-pyrrolidin-1-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide;

(6S)-3-[(5S)-5-methoxy-2-oxo-1,3-oxazinan-3-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; and


(6S)-3-[(5R)-5-methoxy-2-oxo-1,3-oxazinan-3-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide;

or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

35. A process for the preparation of a compound according to any one of claims 1 to 34


comprising any of the following steps:

(a) a reaction of a compound of formula (V),




with an acid followed by urea formation with amine R^4NH_2 in the presence of a phosgene equivalent;

(b) a reaction of a compound of formula (VII),




with an acid followed by urea formation with amine R^4NH_2 in the presence of a phosgene equivalent;

(c) a reaction of a compound of formula (IX),



with $R^7-B(OH)_2$; or

(d) a reaction of a compound of formula (X),



5 with halide via Suzuki-Miyaura reaction;

wherein R^2 , R^3 , R^4 are defined as in any one of claims 1 to 34;

R^5 and R^6 together with the nitrogen atom they are attached to form a 3-7 membered heterocyclyl; and

R^7 is aryl or heteroaryl.

10

36. A compound or pharmaceutically acceptable salts, enantiomers or diastereomers according to any one of claims 1 to 34 for use as therapeutically active substance.

37. A pharmaceutical composition comprising a compound in accordance with any one of claims 15 1 to 34 and a therapeutically inert carrier.

38. The use of a compound according to any one of claims 1 to 34 for the preparation of a medicament for the treatment or prophylaxis of hepatitis B virus infection.

20 39. A compound or pharmaceutically acceptable salt, enantiomer or diastereomer according to any one of claims 1 to 34 for use in the treatment or prophylaxis of hepatitis B virus infection.

40. A compound or pharmaceutically acceptable salt, enantiomer or diastereomer according to any one of claims 1 to 34, when manufactured according to a process of claim 35.

25